Westminster Pharmaceuticals Partners with OEP Pharma to Bring Single-Source Generic Miglitol to the Marketplace
Nashville, TN — January 2021 — Westminster Pharmaceuticals has partnered with OEP Pharma to distribute the single-source generic drug miglitol. OEP Pharma, the U.S. subsidiary of OEP Group, holds the only currently approved ANDA to miglitol. It selected Westminster, a rapidly growing private label distributor, from among several companies to enhance patient access to the anti-diabetic medication.
Miglitol, the generic version of Glyset, is used to control high blood sugar in people with type 2 diabetes. It will be available in 25 mg, 50 mg, and 100 mg tablets. Under the new alliance, OEP will continue to manufacture the product in Taiwan while Westminster will oversee marketing and distribution in North America.
Following a launch starting in February 2021, the product will be available to wholesalers as well as major retailers.
“OEP Pharma’s strong manufacturing capabilities, attentiveness to the quality of products, and consistent on-time delivery make for an ideal collaboration,” said Louis Sanchez, CEO of Westminster. “This alliance will help ensure miglitol reaches more pharmacies, hospitals, and patients across the country.”
“Both OEP and Westminster are focused on improving patient access to high-quality and cost-effective products,” said Elenor Mak, VP of Business Development at OEP Pharma. “Westminster’s track record in the generics market, focus on customer service, and building strong partnerships align with OEP’s mission to deliver the highest quality products at prices patients can afford.”
To learn more about the launch, contact Westminster Pharmaceuticals Head of Business Development Jonathan Olive at jolive@wprx.com.
About Westminster Pharmaceuticals:
Westminster Pharmaceuticals provides timely access to high-quality pharmaceuticals at affordable prices by distributing generic drugs to hospitals, pharmacies, wholesalers, and distributors throughout North America. Founded in 2012 and based out of Nashville, TN, and Tampa, FL, Westminster Pharmaceuticals meets specific market demands by addressing health issues in several key therapeutic areas. An industry leader, Westminster partners with manufacturers and pharmacies around the country to develop new pharmaceutical products, reduce the cost of healthcare, and improve overall patient outcomes. For more information about Westminster Pharmaceuticals, visit WPRX.com.
About OEP Pharma:
OEP Pharma is the U.S. headquarters and a subsidiary of Orient Europharma Co., Ltd, (4120.TWO), a Taiwan Stock Exchange (TWSE)-listed pharmaceutical and consumer health company founded in 1982. A leading distributor of pharmaceutical products in Taiwan and Southeast Asia with operations in 10 countries and over 1000 employees, OEP Pharma develops, manufactures, and distributes branded and generic products. Its orals manufacturing plant was the first in Taiwan to be built in accordance with international standards and certified by the U.S.Food and Drug Administration (FDA). OEP Pharma is actively expanding its generics and specialty pharma portfolio in the U.S. To learn more, visit oeppharma.com.